TOKYO--(BUSINESS WIRE)--May 28, 2026--
AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification *1 based on UL 2809 *2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach *3, 100% *4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the industry-leading levels *5 of recycled material utilization in fluoroelastomer materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528992272/en/
AFLAS™ FFKM is an industrial elastomer that offers one of the highest levels of chemical resistance, heat resistance, and plasma resistance among fluorinated elastomers, and is used in a wide range of applications, particularly in the semiconductor manufacturing sector. Its resistance to degradation under harsh conditions makes it suitable for use in sealing materials and O-rings in applications requiring high reliability and durability.
The AGC Group has been working to recycle waste generated at its own plants and utilize it in fluorine products as Recycled Circular Fluorite. In 2025, the AGC Group was the first in the world to complete third-party verification based on UL 2809 for Fluon™ PTFE. With the completion of this verification, the AGC Group has prepared to offer AFLAS™ FFKM as a product that successfully combines high performance with environmental considerations.
After completing this verification, the AGC Group is ready to introduce AFLAS™ FFKM, a product that blends exceptional performance with environmental awareness.
Under its mid-term management plan AGC plus-2026, the AGC Group identifies “Deepening of Sustainability Management” as one of its key strategies. The Group will continue to actively work toward the realization of a circular economy for fluorine resources.
Reference
Environmental Claim Validation labels for the three AFLAS™ FFKM product lines
NEW YORK--(BUSINESS WIRE)--Jun 1, 2026--
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601532429/en/
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the study design for the Company’s Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites.
On February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from its Phase 3 PROSERA study, announcing that the trial failed to meet its primary endpoint of improving six-minute walk distance (“6MWD”) at Week 24. While the study reported a placebo-adjusted gain of +13.3 meters, the result did not achieve statistical significance under the prespecified alpha threshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to unexpectedly strong placebo performance among patients enrolled at Latin American sites, which it characterized as a heavily treated, lower-risk population.
Following this disclosure, investors and analysts reacted swiftly and negatively. On February 23, 2026, Gossamer’s common stock price plummeted from a closing price of $2.13 per share on February 20, 2026 to $0.42 per share, representing a decline of more than 80% in a single trading day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Gossamer’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Gossamer Bio class action, go to www.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
